pic-adolescent-medicine-clinical-research.jpgThe Section of Adolescent Medicine performs a wide variety of research projects encompassing multiple disciplines. Research projects here are cutting-edge, and many have led to important policy changes that impact the health of communities. Our research teams are all CITI (Collaborative Institutional Training Initiative) certified and uphold the standards of Good Clinical Practices. Our research teams along with the Principal Investigators carry on the long standing tradition of Adolescent Medicine, to continue to ask new questions and turn that knowledge into useful practices that can be translated to our patients and policy decision makers.

Current Research Studies

  • HIV Testing and Women’s Attitudes on HIV Vaccine Trials

  • Adolescent Trial Network (ATN) Coordinating Cente

  • Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV infection in 26- to 45-Year-Old-Women

  • A Placebo-Controlled, Dose Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old-Women

  • Quality of Life in Adolescent & Young Adult Testicular Cancer Survivors

  • Developmental Epidemiology of Incident STI among Adolescent Boys

  • Health care access for delinquent youth

  • HPV Vaccination, Attitudes and Sequential Behaviors in Adolescent Women

  • Urethral Microbiome of Adolescent Males

  • MASP:  Overcoming barriers to Vaccination with Gardasil and Adolescents

  • An investigation of provider-parent-son decision-making about HPV vaccination and preliminary test of the effects of educational messaging on the intent to vaccinate sons

  • Behavioral and Virologic Impact of HPV Immunization

  • A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Given Concomitantly with Menactra and Adacel in Preadolescents and Adolescents (11 to 15 years old)

  • A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16,  and 18) L1 Virus Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18- Related Genital Infections

  • A Randomized International Double-Blinded (with In-House Blinding), Controlled with GARDASIL, Dose-Ranging Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administereds

  • Vulnerability in Medical Research

  • OWL (Our Whole Lives)

  • Relational and contextual phenomenology of STI/HIV risk

For participant study requirements please see: